Psilocybin, psychological distress, and suicidality
Peter S. Hendricks, Matthew W Johnson, Roland R. Griffiths
Journal of Psychopharmacology September 1, 2015 DOI: 10.1177/0269881115598338 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | News report Peer reviewed |
|---|---|
| Population | United States adult population |
| Topics | Psilocybin |
| Keywords | Psychological distress Hallucinogen Clinical psychology Psychotherapist |
| Citations | 107 |
| Key points | Hendricks et al. (2015) reported that ever having used any classic psychedelic substance was associated with lower odds of past-month psychological distress (weighted OR = 0.81), past-year suicidal thinking (weighted OR = 0.86), past-year suicidal planning (weighted OR = 0.71), and past-year suicide attempt (weighted OR = 0.64) in the United States adult population. |
Abstract
Hendricks et al. (2015) found that having ever used any classic psychedelic substance—namely, dimethyltryptamine (DMT), ayahuasca, lysergic acid diethylamide (LSD), mescaline, peyote or San Pedro, or psilocybin—was associated with a significantly reduced likelihood of past month psychological distress (weighted OR = . 81 (. 72–. 91)), past year suicidal thinking (weighted OR = . 86 (. 78–. 94)), past year suicidal planning (weighted OR = . 71 (. 54–. 94)), and past year suicide attempt (weighted OR = . 64 (. 46–. 89)) in the United States adult population.
Citations in the library
Cited by 92
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences Journal of Psychopharmacology August 31, 2016
- Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacology & Therapeutics May 1, 2019
- The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act Neuropharmacology June 5, 2018
- Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. Journal of Psychopharmacology February 2, 2022
and 87 more in the library
Cites 8
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
- Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study Journal of Psychopharmacology January 13, 2015
- Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Journal of Psychopharmacology September 11, 2014
- Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. Journal of Psychopharmacology March 1, 2015
- Psychedelics not linked to mental health problems or suicidal behavior: A population study Journal of Psychopharmacology March 1, 2015
and 3 more in the library